Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis With Severe Endoscopic Disease
Among biologic-naïve UC patients with severe endoscopic disease, infliximab and upadacitinib had the highest rates of week 2 and postinduction PRO-2 response. Baseline disease activity may help to better inform treatment choices.
Authors
- N Narula
- Emily CL Wong
- C Ma
- John K. Marshall
- Walter Reinisch
- Vipul Jairath
- Parambir S. Dulai
Institutions
- Northwestern University (US)
- Western University (CA)
- University of Calgary (CA)
- Population Health Research Institute (CA)
- Medical University of Vienna (AT)
- McMaster University (CA)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2026-02-02
- DOI
- https://doi.org/10.14309/ajg.0000000000003940
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00